Karolinska Development AB has agreed to take control of a preclinical leukaemia project from Biovitrum AB of Stockholm. The project aims to develop new compounds for leukaemia by inhibiting the activity of the tyrosine kinase receptor, FLT3.
Karolinska Development AB has agreed to take control of a preclinical leukaemia project from Biovitrum AB of Stockholm. The project aims to develop new compounds for leukaemia by inhibiting the activity of the tyrosine kinase receptor, FLT3.